CD47 antibodies, such as the humanized B6H12 (often referred as B6H12.2) and BRIC126 (Table 1) have been shown to be effective in pre-clinical mouse models of acute myeloid leukemia (AML) (19), acute lymphoblastic leukemia (27), T-cell lymphoma (TCL) (54), and various solid tumors. Here, CD47 is linked to acute myeloid leukemia.